Enanta Pharmaceuticals (ENTA) Releases Quarterly Earnings Results, Misses Expectations By $0.21 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) released its quarterly earnings data on Wednesday. The biotechnology company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.21), Bloomberg Earnings reports. The company had revenue of $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a net margin of 34.82% and a return on equity of 21.56%. The business’s revenue was up 83.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.59 EPS.

NASDAQ ENTA opened at $83.77 on Thursday. Enanta Pharmaceuticals has a 12-month low of $64.08 and a 12-month high of $127.77. The firm has a market capitalization of $1.63 billion, a P/E ratio of 24.07 and a beta of 1.27.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Enanta Pharmaceuticals by 6.5% in the 3rd quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after purchasing an additional 157,166 shares during the period. Vanguard Group Inc. grew its position in Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after purchasing an additional 330,374 shares during the period. Vanguard Group Inc grew its position in Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after purchasing an additional 330,374 shares during the period. First Manhattan Co. grew its position in Enanta Pharmaceuticals by 22.7% in the 3rd quarter. First Manhattan Co. now owns 698,434 shares of the biotechnology company’s stock valued at $59,688,000 after purchasing an additional 129,026 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Enanta Pharmaceuticals by 1.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 604,006 shares of the biotechnology company’s stock valued at $51,620,000 after purchasing an additional 10,159 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently weighed in on ENTA shares. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 19th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, November 20th. Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, November 27th. Finally, Berenberg Bank started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, December 13th. They issued a “hold” rating and a $80.00 price objective for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $100.00.

WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2019/02/06/enanta-pharmaceuticals-enta-announces-quarterly-earnings-results.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: Buyback

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply